To Conduct a Prospective Study on Pioglitazone Induced Kidney Injury in Tertiary Care Hospital
Abstract
Conducting a prospective study on kidney impairment caused by pioglitazone at tertiary care hospitals is the study's goal. The goal is to assess Pioglitazone, mortality, quality of life, and the degree of the medication's harmful side effects in diabetic patients. According to the "Pioglitazone-induced kidney injury" prospective study. Out of 350 trial participants, prolonged pioglitazone use in diabetic patients has been shown to raise serum creatinine levels by up to 11%. Additionally, individuals who have been using pioglitazone for six to ten years are more likely to experience renal injury, with males in the 50–60 year age range being the most common victims.
Keywords: Pioglitazone, diabetic, prospective, tertiary care, hospital.
Keywords:
Pioglitazone, diabetic, prospective, tertiary care, hospitalDOI
https://doi.org/10.22270/jddt.v14i1.6183References
Torella R, Lunetta M, Vitali L, Repaglinide plus bedtime insulin is as effective as premixed insulin twice daily but more safe than insulin alone in Type 2 diabetes mellitus inadequately controlled with oha therapy. Diabetologia, 2002; 45:765.
Diana LR, Ira CS. Evaluation of the Quality of Life of Chronic Kidney Failure Patients Undergoing Hemodialysis at General Hospital in Jakarta. International Journal of Experimental and Biomedical Research, 2022; 1(1):6-13.
Jin HM, Pan Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res 2007; 30: 203-11. https://doi.org/10.1159/000104089 PMid:17575467
Hari Chandana G, Yerikala Ramesh, Venugopalaiah P, Prapurna Chandra Y, Prospective study on meglitinide induced kidney injury in tertiary care hospital, GSC Biological and Pharmaceutical Sciences, 2023; 25(01):211-219. https://doi.org/10.30574/gscbps.2023.25.1.0421
Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diabetic Medicine 2000;17(3):225‐9. https://doi.org/10.1046/j.1464-5491.2000.00256.x PMid:10784228
Brogard JM, Landin‐Olsson M, Eriksson J. Repaglinide with bedtime insulin improves glycaemic control in poorly controlled type 2 diabetes. Diabetologia 2000;43:716.
James MT, Bhatt M, Pannu N, Tonelli M. Long-term outcomes of acute kidney injury and strategies for improved care. Nature Reviews Nephrology, 2020; 16:193-205. https://doi.org/10.1038/s41581-019-0247-z PMid:32051567
Reel B, Guzeloglu M, Bagriyanik A, Atmaca S, Aykut K, Albayrak G, The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats. Journal of Surgical Research, 2013; 182:176-184. https://doi.org/10.1016/j.jss.2012.08.020 PMid:22981741
Sahithi Maroju, Krishna Sumanth K. Prescription Pattern: Diabetes Mellitus in a Tertiary Care Hospital. International Journal of Clinical Pharmacokinetics and Medical Sciences, 2021; 1(3):108-114.
Shigeo N, Daisuke K, Sou K, Takuro Y, Koichi T, Toru M, Takashi S, Masaki O, Acute kidney injury: Epidemiology, outcomes, complications, and therapeutic strategies. Seminars in Dialysis, 2018; 31(5):519-527. https://doi.org/10.1111/sdi.12705 PMid:29738093
Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y, Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2020; 105:1670-1681. https://doi.org/10.1210/clinem/dgz252 PMid:31822895
Zhou D, Li Y, Lin L, Zhou L, Igarashi P, Liu Y. Tubule-specific ablation of endogenous β-catenin aggravates acute kidney injury in mice. Kidney Int. 2012; 82:537-47. https://doi.org/10.1038/ki.2012.173 PMid:22622501 PMCid:PMC3425732
Manjunath G Gandage, Kukunuri Dinesh Kumar, Paturu Venkatesh, Basavaraj Kesapur, Effectiveness of Oral Hypoglycaemics in Type-2 Diabetes Mellitus Patients at a Tertiary Care Hospital : A Comparative Observational Study. Future Journal of Pharmaceuticals and Health Sciences, 2022; 2(4):321-327. https://doi.org/10.26452/fjphs.v2i4.330
Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020; 383:1436-1446. https://doi.org/10.1056/NEJMoa2024816 PMid:32970396
Priyamvada PS, Jayasurya R, Shankar V, Parameswaran S. Epidemiology and outcomes of acute kidney injury in critically ill: Experience from a tertiary care center. Indian Journal of Nephrology. 2018; 28:413-420. https://doi.org/10.4103/ijn.IJN_191_17 PMid:30647494 PMCid:PMC6309393
Umesh L, Shivaprasad SM, Niranjan MR, Leelavathi V, Sreedhara CG, Rajiv EN. Acute kidney injury: Experience from a state run tertiary care centre in southern India. International Journal of Medical Research and Health Sciences, 2016;5:83-7
Published
Abstract Display: 445 
PDF Downloads: 503 PDF Downloads: 188 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.